Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...

Friday’s jobs report could bolster the view that the American economy is holding steady, but an oil price shock could ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

LEBANON, Ind. (WFFT) — Eli Lilly and Company announced another $4.5 billion investment in Lebanon’s LEAP Research and ...

With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

AUSTIN — Attorney General Ken Paxton sued major pharmaceutical makers and other companies Thursday, alleging they violated ...

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...

The state of Texas is accusing major pharmacy benefit managers and drug companies of colluding to raise the cost of insulin.